Screener
Absci Corporation ABSI Drug creation program and platform — R&D
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Absci Corporation in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Absci Corporation’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001672688-26-000136
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Drug creation programs and platform (1) | $6,045 | $5,289 | $12,128 | $9,295 |
| External preclinical and clinical development (2) | 6,852 | 5,370 | 11,139 | 8,054 |
| Personnel (3) | 9,569 | 10,283 | 18,815 | 20,148 |
| Stock-based compensation | 5,245 | 4,752 | 9,625 | 9,697 |
| General & administrative | 4,032 | 3,538 | 8,366 | 7,860 |
| Depreciation and amortization | 2,696 | 3,000 | 5,424 | 6,072 |
| Other (gain)/loss, net (4) | 37 | (246) | 40 | (232) |
| Total operating expenses | $34,476 | $31,986 | $65,537 | $60,894 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Absci Corporation's drug creation program and platform — R&D?
- Absci Corporation (ABSI) reported drug creation program and platform — R&D of $6.05M in Q2 2026.
- How has Absci Corporation's drug creation program and platform — R&D changed year-over-year?
- Absci Corporation's drug creation program and platform — R&D increased by 14.3% year-over-year, from $5.29M to $6.05M.
- What is the long-term trend for Absci Corporation's drug creation program and platform — R&D?
- Over 2 years (2023 to 2025), Absci Corporation's drug creation program and platform — R&D has grown at a 21.8% compound annual growth rate (CAGR), from $13.71M to $20.35M.
- What does drug creation program and platform — R&D mean?
- This metric represents the total operating expenses allocated to the research and development of the company's proprietary drug discovery platform and internal therapeutic programs. It captures the investment in synthetic biology, artificial intelligence, and cell line development technologies required to advance novel biologics. Monitoring this spend provides insight into the company's commitment to innovation and the scalability of its drug creation capabilities.
Ask your AI about Absci Corporation's drug creation program and platform — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude